Oxygen‐independent degradation of HIF‐α via bioengineered VHL tumour suppressor complex
Open Access
- 26 March 2009
- journal article
- Published by European Molecular Biology Organization in EMBO Molecular Medicine
- Vol. 1 (1), 66-78
- https://doi.org/10.1002/emmm.200900004
Abstract
Tumour hypoxia promotes the accumulation of the otherwise oxygen-labile hypoxia-inducible factor (HIF)-α subunit whose expression is associated with cancer progression, poor prognosis and resistance to conventional radiation and chemotherapy. The oxygen-dependent degradation of HIF-α is carried out by the von Hippel–Lindau (VHL) protein-containing E3 that directly binds and ubiquitylates HIF-α for subsequent proteasomal destruction. Thus, the cellular proteins involved in the VHL–HIF pathway have been recognized as attractive molecular targets for cancer therapy. However, the various compounds designed to inhibit HIF-α or HIF-downstream targets, although promising, have shown limited success in the clinic. In the present study, we describe the bioengineering of VHL protein that removes the oxygen constraint in the recognition of HIF-α while preserving its E3 enzymatic activity. Using speckle variance–optical coherence tomography (sv–OCT), we demonstrate the dramatic inhibition of angiogenesis and growth regression of human renal cell carcinoma xenografts upon adenovirus-mediated delivery of the bioengineered VHL protein in a dorsal skin-fold window chamber model. These findings introduce the concept and feasibility of ‘bio-tailored’ enzymes in the treatment of HIF-overexpressing tumours.Keywords
This publication has 50 references indexed in Scilit:
- Dominant-Negative HIF-3α4 Suppresses VHL-Null Renal Cell Carcinoma ProgressionCell Cycle, 2007
- VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and SnailMolecular and Cellular Biology, 2007
- Role of the NEDD8 Modification of Cul2 in the Sequential Activation of ECV ComplexNeoplasia, 2006
- Differentiating the functional role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α (EPAS‐1) by the use of RNA interference: erythropoietin is a HIF‐2α target gene in Hep3B and Kelly cellsThe FASEB Journal, 2004
- von Hippel-Lindau Tumor Suppressor Protein and Hypoxia-Inducible Factor in Kidney CancerAmerican Journal of Nephrology, 2004
- Targeted degradation of β-catenin by chimeric F-box fusion proteinsBiochemical and Biophysical Research Communications, 2004
- Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor GrowthPLoS Biology, 2003
- Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma CellsPublished by Elsevier BV ,2003
- Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylationThe EMBO Journal, 2001
- Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor proteinThe EMBO Journal, 2000